Jin Yang Pharmaceutical Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	120,686	113,332	94,111	76,264	62,839
Other Revenue	-	-0	-	-0	-
Revenue	120,686	113,332	94,111	76,264	62,839
Revenue Growth (YoY)	6.49%	20.42%	23.40%	21.36%	26.88%
Cost of Revenue	42,535	43,448	36,652	30,613	28,856
Gross Profit	78,151	69,884	57,459	45,651	33,984
Selling, General & Admin	72,891	59,052	46,381	33,981	27,965
Other Operating Expenses	657.35	205.11	170.02	139.73	146.93
Operating Expenses	75,625	58,175	48,374	34,513	27,020
Operating Income	2,526	11,708	9,085	11,138	6,964
Interest Expense	-2,292	-1,855	-1,374	-1,285	-208.28
Interest & Investment Income	41.68	481.5	1,472	356.59	16.99
Currency Exchange Gain (Loss)	-1.41	-2.38	-1.69	3.53	-0.2
Other Non Operating Income (Expenses)	-1,093	2,439	937.36	839.11	3,913
EBT Excluding Unusual Items	-818.66	12,771	10,119	11,053	10,685
Gain (Loss) on Sale of Investments	28,888	24,298	2,253	3,132	1,438
Gain (Loss) on Sale of Assets	31.33	-77.14	0.86	24.9	9.53
Asset Writedown	-	-	-	325.53	-
Other Unusual Items	-	62.21	210.2	-	-
Pretax Income	28,101	37,054	12,583	14,535	12,132
Income Tax Expense	5,814	7,360	-75.78	2,227	2,594
Net Income	22,287	29,694	12,659	12,308	9,538
Net Income to Common	22,287	29,694	12,659	12,308	9,538
Net Income Growth	-24.95%	134.57%	2.85%	29.05%	82.41%
Shares Outstanding (Basic)	-	11	11	11	11
Shares Outstanding (Diluted)	-	12	12	13	11
Shares Change (YoY)	-	-1.17%	-7.18%	17.77%	2.12%
EPS (Basic)	-	2692.30	1174.67	1114.86	853.30
EPS (Diluted)	-	2408.01	1014.53	915.61	835.60
EPS Growth	-	137.35%	10.80%	9.57%	78.63%
Free Cash Flow	-2,801	-77,268	7,851	4,230	-545.86
Free Cash Flow Per Share	-	-6265.96	629.22	314.65	-47.82
Gross Margin	64.76%	61.66%	61.06%	59.86%	54.08%
Operating Margin	2.09%	10.33%	9.65%	14.61%	11.08%
Profit Margin	18.47%	26.20%	13.45%	16.14%	15.18%
Free Cash Flow Margin	-2.32%	-68.18%	8.34%	5.55%	-0.87%
EBITDA	4,935	13,733	11,740	13,429	9,117
EBITDA Margin	4.09%	12.12%	12.47%	17.61%	14.51%
D&A For EBITDA	2,409	2,024	2,655	2,291	2,154
EBIT	2,526	11,708	9,085	11,138	6,964
EBIT Margin	2.09%	10.33%	9.65%	14.61%	11.08%
Effective Tax Rate	20.69%	19.86%	-	15.32%	21.38%
Advertising Expenses	3,268	3,748	3,869	2,541	2,125

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.